Sign up for Englemed updates from TwitterSign up for Englemed updates from Facebook
Contact Englemed
Our contact email address.
We can provide a specialist, tailored health and medical news service for your site.
Click here for more information
RSS graphic XML Graphic Add to Google
About Englemed news services - services and policies.
Englemed News Blog - Ten years and counting.
Diary of a reluctant allergy sufferer - How the British National Health Service deals with allergy.
BookshopFor books on women's health, healthy eating ideas, mental health issues, diabetes, etc click here
Copyright Notice. All reports, text and layout copyright Englemed Ltd, 52 Perry Avenue, Birmingham UK B42 2NE. Co Registered in England No 7053778 Some photos copyright Englemed Ltd, others may be used with permission of copyright owners.
Disclaimer: Englemed is a news service and does not provide health advice. Advice should be taken from a medical professional or appropriate health professional about any course of treatment or therapy.
Study to look at Covid-19 impact on blood cancer patients
Fri May 22nd - A new UK study is to be launched that will examine how patients who receive stem cell transplants for blood cancers and blood disorders react to severe Covid-19 infection. More
'Focus on blood clotting in Covid-19 patients'
Fri May 22nd - There is an urgent need to focus on medications that address dangerous blood clotting in Covid-19 patients, according to a leading haematologist. More
Immunotherapy hope for elimination of leukaemia stem cells
Fri May 22nd - Hematopoietic stem cells can be selectively eliminated using immunotherapy instead of chemotherapy, a new Swiss study has revealed. More
On 08/02/2018 David Kelly wrote:
Would you like to write a piece about this to be i... on Researchers unveil new pain re...
On 23/10/2017 Cristina Pereira wrote: on HIV breakthrough - MRC...
On 12/09/2017 Aparna srikantam wrote:
Brilliant finding! indeed a break through in under... on Leprosy research breakthrough...
On 01/07/2017 Annetta wrote:
I have been diagnosed with COPD for over 12 years.... on Seaweed plan for antimicrobial...
On 12/03/2017 Steph wrote:
The photo you have paired with this article is its... on 'Fat shaming' limits...
guide to breast disorders guide to womb disorders guide to menopause Complete Women's Health: from The Royal College of Obstetricians and Gynaecologists For books and family gift ideas click here
RSS graphic XML Graphic

Blood test identifies rare breast cancer mutations

Friday December 13th, 2019

Rare mutations in advanced breast cancer can be identified through a simple blood test, in what clinicians have described as a “huge step”, it was announced last night.

Cancer Research UK scientists undertook a study as part of the plasmaMATCH clinical trial and detected mutations in the DNA from tumours in the bloodstream.

They also found specific weaknesses in the breast cancer DNA that could be targeted with drugs.

This suggests that the blood test would provide better guidance for treatment compared to biopsies, they report.

The team, from the Institute of Cancer Research, London, and The Royal Marsden NHS Foundation Trust, presented the results at the 2019 San Antonio Breast Cancer Symposium yesterday (12 December 2019).

The study, undertaken to see if taking a liquid biopsy is quicker and easier than traditional tumour testing, involved the analysis of blood from about 1,000 women whose breast cancer had returned after treatment, or had spread to another part of the body.

The research team wanted to see if a blood test could detect three targetable defects in HER2, ESR1 and AKT1 genes, all of which are known to drive breast cancer.

They examined 142 women with the detectable mutations who were given experimental targeted therapies to attack the specific characteristics of their cancer. The researchers found that the treatments are promising but will undertake further tests in larger clinical trials.

The researchers also checked tissue samples from the patients and found the liquid biopsy had correctly identified the presence or absence of the mutations in more than 95% of cases.

Professor Nicholas Turner, professor of molecular oncology at The Institute of Cancer Research, London, and consultant medical oncologist at The Royal Marsden, said: “The choice of targeted treatment we give to patients is usually based on the mutations found in the original breast tumour. But their cancer can have different mutations after it has moved to other parts of the body.

“We have now confirmed that blood tests can quickly give us a bigger picture of the mutations are present within multiple tumours throughout the body, getting the results back to patients accurately and faster than we could before.

“This is a huge step in terms of making decisions in the clinic, particularly for those women with advanced breast cancer who could quickly be put on new targeted treatments matched to their cancer if it evolves to become drug resistant.”

The researchers believe the blood tests are now reliable enough to be used routinely by doctors, once they have passed regulatory approval.

GS3-06. Turner, N et al. Results from the plasmaMATCH trial: A multiple parallel cohort, multi-centre clinical trial of circulating tumour DNA testing to direct targeted therapies in patients with advanced breast cancer (CRUK/15/010). San Antonio Breast Cancer Symposium 12 December 2019

GS3-07. Kingston, B et al. The genomic landscape of breast cancer based on ctDNA analysis: data from the plasmaMATCH trial. San Antonio Breast Cancer Symposium 12 December 2019

Tags: Cancer | Genetics | Women's Health & Gynaecology

Printer friendly page Printer friendly page

Comment on this article:

<a>,<b> & <p> tags allowed
Please enter the letters displayed:
(not case sensitive)